AXGN
NasdaqAXOGEN, INC.
Technology · Electromedical & Electrotherapeutic Apparatus
Research view
Fundamentals · SEC EDGAR · FY 2025-12-31
Revenue & Earnings — fiscal year
$127.4M
2021
$138.6M
2022
$159.0M
2023
$187.3M
2024
$225.2M
2025
Snapshot
SEC EDGAR · FY 2025-12-31Revenue$225.2M
Net Income$-15.7M
Gross Profit$167.4M
Oper Income$-7.8M
EPS (dil)$-0.34
Rev/sh$4.23
FCF/sh$-0.06
Book/sh$2.42
Gross M74.3%
Oper M-3.5%
Profit M-7.0%
FCF M-1.3%
ROE-12.2%
ROA-7.1%
ROIC-5.6%
R&D/Rev14.6%
Rev Y/Y20.2%
Rev 3Y CAGR17.6%
EPS Y/Y-47.8%
EPS 3Y CAGR—
FCF 3Y CAGR—
Payout—
Div/sh—
Shs Chg Y/Y+4.1%
Current Ratio5.11
Quick Ratio3.31
Debt/Eq0.39
Int Coverage-1.0×
Net Debt$11.3M
Total Debt$50.9M
Cash & Eq$39.5M
Total Assets$221.7M
Oper CF$812,000
Capex$3.7M
Free CF$-2.9M
Buybacks—
Equity$128.8M
Liabilities$92.8M
Shs Outstand0.05B
SectorTechnology
🔒 P/E—
🔒 Fwd P/E—
🔒 P/S—
🔒 P/B—
🔒 Market Cap—
🔒 Div Yield—
🔒 52W Range—
🔒 Beta—
40+ fundamentals — free from SEC EDGAR (public domain). Only the 🔒 price-derived column needs a market-data feed.
Financials — annual
SEC EDGAR · last 5 FY| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $127.4M | $138.6M | $159.0M | $187.3M | $225.2M |
| Gross Profit | $104.4M | $108.8M | $121.9M | $142.0M | $167.4M |
| Operating Income | $-25.4M | $-29.7M | $-21.5M | $-3.3M | $-7.8M |
| Net Income | $-27.0M | $-28.9M | $-21.7M | $-10.0M | $-15.7M |
| Diluted EPS | $-0.65 | $-0.69 | $-0.51 | $-0.23 | $-0.34 |
| Operating Cash Flow | $-13.4M | $-16.1M | $-5.7M | $4.5M | $812,000 |
| Free Cash Flow | $-41.2M | $-36.1M | $-19.6M | $1.4M | $-2.9M |
COMMUNITY · $AXGN0 theses
POST YOUR TAKE →Fundamentals sourced from SEC EDGAR filings (public domain). For informational purposes only. Not investment advice.